PMVP earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -0.89. Updated 2026-07-23.
PMV Pharmaceuticals (PMVP) Research Hub
PMV Pharmaceuticals (PMVP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.13 USD (-11.02%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.89, market cap 0.07B. This hub links to the full technical, earnings and options research available for PMVP.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.13 USD (-11.02%) |
| 52-week range | 1.05 USD – 1.91 USD |
| Trend regime | Range |
| 14-day RSI | 26 (Oversold) |
| Trailing P/E | -0.89 |
| Market cap | 0.07B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for PMVP
Covered Call on PMVP: how it works, illustrative setup around the real 1.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PMVP: how it works, illustrative setup around the real 1.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PMVP: how it works, illustrative setup around the real 1.13 USD price, max profit/loss, breakeven and when to use it. Educational.
PMVP technical analysis: range, last 1.13 USD, RSI 26, 52w range 1.05 USD–1.91 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is PMVP in?
PMV Pharmaceuticals (PMVP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PMVP in an uptrend or downtrend?
As of 2026-10-26, PMVP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PMVP's trailing P/E ratio?
PMVP's trailing P/E is -0.89, with a market cap of 0.07B. See the earnings research page for full valuation detail.
When does PMVP next report earnings?
PMVP is next scheduled to report earnings on 2026-08-06.